Duke University Center for Applied Therapeutics
The Center for Applied Therapeutics in the Department of Surgery at Duke University encompasses a broad array of research activities involved in the development, preclinical testing, and clinical testing of novel therapies targeting cancer or precancerous conditions. Collectively, the Center for Applied Therapeutics consists of over 30 individuals ranging from senior scientists to post-doctoral fellows, which serves as a robust environment for research activity in a broad array of applied therapeutics.
Dr. H. Kim Lyerly, M.D., F.A.C.S, is the director for The Center for Applied Therapeutics. He is the George Barth Geller Professor in Cancer Research, and Professor of Surgery, Immunology and Pathology at Duke University. Dr. Lyerly is an internationally recognized expert in cancer therapy and immunotherapy, has published over 300 scientific articles and book chapters and has edited 10 textbooks on surgery, cancer immunotherapy and novel cancer therapies.
Harvard-MIT Center for Regulatory Science
Formed in partnership with Harvard Medical School, MIT, and a memorandum of understanding with the U.S. Food and Drug Administration (FDA), this center is a collaborative forum for scientists, engineers and physicians from academic research institutions, pharmaceutical and biotechnology companies, and the FDA to jointly investigate innovative strategies for effective development and evaluation of therapeutic products. The Center will accelerate the introduction of new treatments for disease, determine how best to identify patients who will benefit from these treatments and reduce the economic burden of biomedical innovation.